Literature DB >> 10050879

MDM2 overexpression generates a skin phenotype in both wild type and p53 null mice.

M Alkhalaf1, G Ganguli, N Messaddeq, M Le Meur, B Wasylyk.   

Abstract

The MDM2 proto-oncogene is overexpressed in human tumours and regulates the activities of the tumour suppressors p53 and pRB. We created mice that overexpress MDM2 under the control of the CMV promoter. These mice did not display an increased tumour incidence, but rather a specific skin phenotype, characterized by desquamation and hyperkeratosis. Transgenic MDM2 was found to be overexpressed in the epidermis, a tissue that normally expresses high levels of MDM2. The phenotype appeared during the first week after birth and then lessened with age, closely following the level of expression of the transgene. MDM2 overexpression was associated with an increase in proliferation in the basal layer, thickening of the epidermis, altered expression of the differentiation markers cytokeratin CK14, CK10 and CK1, and a decrease in the size and the number of granules that contain products of differentiation. Transgenic mice on a p53 null background displayed similar although not identical changes, showing that the effects of MDM2 are to a certain degree p53 independent. The skin is a major site of MDM2 expression in mice, raising the possibility that MDM2 overexpression perturbs the normal pattern of MDM2 expression and inhibits differentiation of the epidermis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10050879     DOI: 10.1038/sj.onc.1202448

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

Review 1.  MDM2 and mitochondrial function: One complex intersection.

Authors:  Camila Rubio-Patiño; Andrew Paul Trotta; Jerry Edward Chipuk
Journal:  Biochem Pharmacol       Date:  2018-11-01       Impact factor: 5.858

2.  The RING finger domain of MDM2 is essential for MDM2-mediated TGF-beta resistance.

Authors:  Christian Kannemeier; Rong Liao; Peiqing Sun
Journal:  Mol Biol Cell       Date:  2007-04-11       Impact factor: 4.138

3.  Identifying a hyperkeratosis signature in autosomal recessive congenital ichthyosis: Mdm2 inhibition prevents hyperkeratosis in a rat ARCI model.

Authors:  Gehad Youssef; Masahiro Ono; Stuart J Brown; Veronica A Kinsler; Neil J Sebire; John I Harper; Ryan F L O'Shaughnessy
Journal:  J Invest Dermatol       Date:  2013-09-04       Impact factor: 8.551

4.  A small nuclear RNA, hdm365, is the major processing product of the human mdm2 gene.

Authors:  S Bartl; J Ban; H Weninger; G Jug; H Kovar
Journal:  Nucleic Acids Res       Date:  2003-02-15       Impact factor: 16.971

5.  MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis.

Authors:  G Ganguli; J Abecassis; B Wasylyk
Journal:  EMBO J       Date:  2000-10-02       Impact factor: 11.598

6.  A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.

Authors:  Hongmei Nan; Abrar A Qureshi; David J Hunter; Jiali Han
Journal:  Cancer Causes Control       Date:  2008-09-24       Impact factor: 2.506

7.  In Vitro Differentiation Potential of Human Placenta Derived Cells into Skin Cells.

Authors:  Ruhma Mahmood; Mahmood S Choudhery; Azra Mehmood; Shaheen N Khan; Sheikh Riazuddin
Journal:  Stem Cells Int       Date:  2015-07-01       Impact factor: 5.443

Review 8.  Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.

Authors:  Qin Li; Guillermina Lozano
Journal:  Clin Cancer Res       Date:  2012-12-21       Impact factor: 12.531

9.  A mitosis block links active cell cycle with human epidermal differentiation and results in endoreplication.

Authors:  Jennifer Zanet; Ana Freije; María Ruiz; Vincent Coulon; J Ramón Sanz; Jean Chiesa; Alberto Gandarillas
Journal:  PLoS One       Date:  2010-12-20       Impact factor: 3.240

Review 10.  The mysterious human epidermal cell cycle, or an oncogene-induced differentiation checkpoint.

Authors:  Alberto Gandarillas
Journal:  Cell Cycle       Date:  2012-10-31       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.